CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosis: A pooled analysis of the Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 3 and 4 trials Anatomical and Functional Computed Tomography for Diagnosing Hemodynamically Significant Coronary Artery Disease: A Meta-Analysis Coronary Microcirculation Downstream Non-Infarct-Related Arteries in the Subacute Phase of Myocardial Infarction: Implications for Physiology-Guided Revascularization Treatment of calcified coronary lesions with Palmaz-Schatz stents. An intravascular ultrasound study Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients Characteristics of abnormal post-stent optical coherence tomography findings in hemodialysis patients Lesion-Specific and Vessel-Related Determinants of Fractional Flow Reserve Beyond Coronary Artery Stenosis Updated clinical classification of pulmonary hypertension Effect of low-density lipoprotein cholesterol on the geometry of coronary bifurcation lesions and clinical outcomes of coronary interventions in the J-REVERSE registry Update on chronic thromboembolic pulmonary hypertension

Guideline2016 Jan 1;37(1):67-119.

JOURNAL:Eur Heart J. Article Link

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)

Galiè N, Humbert M, ESC Scientific Document Group. Keywords: Chronic thromboembolic pulmonary hypertension; Congenital heart disease; Connective tissue disease; Endothelin receptor antagonists; Guidelines; Heart failure; Left heart disease; Lung disease; Phosphodiesterase type 5 inhibitors; Prostacyclin analogues; Pulmonary arterial hypertension; Pulmonary hypertension; Respiratory failure

Full Text PDF